Syn-Coll: skin-firming cosmetic peptide (Palmitoyl Tripeptide-5)
A synthetic skincare ingredient that signals skin cells to make more collagen, helping reduce wrinkles; used in cosmetic creams and serums, not an approved drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Syn-Coll is a synthetic skin-care peptide developed by Pentapharm (now dsm-firmenich) in Switzerland and sold commercially as SYN-COLL. It belongs to a class called signal peptides — short amino-acid sequences designed to trigger the skin's own collagen-making machinery rather than depositing collagen directly. The active peptide is lysine-valine-lysine (KVK), conjugated at the N-terminus to a palmitic acid (C16 fatty acid) chain that improves partitioning into the lipid-rich outer skin layer. This conjugated form is listed under INCI nomenclature as Palmitoyl Tripeptide-5 and is also referenced commercially as Palmitoyl Tripeptide-3; the stored three-letter sequence KVK represents only the bare peptide backbone — the palmitoyl chain is absent from that notation but is the part of the molecule responsible for skin delivery. Syn-Coll is used exclusively as a topical cosmeceutical ingredient; it has no approved drug status in any jurisdiction and no established injectable or systemic application.
History
Syn-Coll was developed by Pentapharm in Switzerland in the early 2000s, building on the company's matrikine peptide program that also produced the Matrixyl-family lipopeptides (Pal-KTTKS, Pal-GHK, Pal-GQPR). The design rationale drew from matricellular biology: thrombospondin-1 (TSP-1), a major extracellular matrix glycoprotein, is one of the principal in vivo activators of latent TGF-β, and its activating function maps to a short KRFK sequence in TSP-1's second type 1 repeat (Robertson and colleagues, Cold Spring Harbor Perspectives in Biology, 2016). Pentapharm's approach was to compress that activation chemistry into a synthetic tripeptide (Pal-Lys-Val-Lys) intended to engage the same TGF-β activation mechanism while being practical to formulate as a topical cosmetic active at concentrations in the 1–3% range. The peptide rode the early 2000s wave of "collagen-stimulating peptide" cosmeceutical positioning and has since been incorporated into a wide range of anti-aging serums and creams. Independent academic literature focused specifically on Syn-Coll as a single ingredient has remained limited; most efficacy data trace to manufacturer-associated studies by Pentapharm and its successor dsm-firmenich.
What it does
Applied to the skin, Syn-Coll is designed to work on two fronts: stimulating fibroblasts — the cells in the dermis that make collagen — to produce more type I and type III collagen, and simultaneously suppressing the enzymes (MMP-1 and MMP-3) that break down existing collagen. The net intended effect is a slow, gradual increase in the skin's collagen content, translating into reduced wrinkle depth and improved firmness over weeks of regular use. These are modest, incremental changes rather than dramatic remodeling; manufacturer-sponsored clinical studies in small cohorts reported roughly 7–12% wrinkle-depth reduction after 84 days of twice-daily topical application, with most subjects in one study reporting a subjective improvement in skin firmness at four weeks.
Evidence
- Human: Small manufacturer-sponsored placebo-controlled study (n=45 volunteers, 84 days, twice-daily topical application) measured wrinkle depth by PRIMOS 3D surface topography and reported approximately 7% reduction at 1% concentration and 12% reduction at 2.5% concentration versus placebo. A separate four-week study in 33 female volunteers using 2.5% Syn-Coll reported 77% of subjects noticed improved firmness and elasticity and 60% reported reduced pore size (self-reported outcomes, no comparator arm). A 28-day study in 15 women using a nanoliposome formulation combining Syn-Coll with Argireline and carnosine reported 25% wrinkle volume reduction and 36.6% elasticity improvement; multi-ingredient design prevents attribution to Syn-Coll specifically. All identified human clinical evidence is manufacturer-associated (Pentapharm/DSM); no independent controlled trials of Syn-Coll as a single ingredient have been identified.
- In vitro: Manufacturer-associated human dermal fibroblast studies showed increased type I and type III collagen mRNA expression and protein levels, and downregulation of MMP-1 and MMP-3, following Syn-Coll treatment. Independent replication in peer-reviewed literature has not been identified.
- Mechanistic basis: The TSP-1–mediated activation of latent TGF-β via the KRFK/LSKL interface is one of the best-characterized mechanisms in extracellular matrix research (Robertson and colleagues 2016; Martinez-Hackert and colleagues, Cytokine & Growth Factor Reviews, 2021; Tzavlaki and colleagues, Biomolecules, 2020). The specific claim that Syn-Coll's KVK sequence functionally mimics TSP-1's KRFK activation motif at the LAP interface is plausible but rests primarily on manufacturer assertion; independent structural or biochemical confirmation has not been identified.
Known effects
- Wrinkle depth reduction (topical) — Preliminary; small manufacturer-sponsored placebo-controlled studies (n=15–45); ~7–12% reduction over 84 days at 1–2.5% concentration.
- Skin firmness and elasticity improvement (topical) — Preliminary; self-reported outcomes in a small n=33 study; single sponsor; no objective comparator.
- Type I and III collagen stimulation via TGF-β activation — Preliminary; supported by manufacturer-associated in vitro fibroblast data and established TSP-1/TGF-β pathway biology; peptide-specific KVK/KRFK mimicry not independently confirmed in vivo.
- MMP-1 and MMP-3 inhibition — Limited; manufacturer-associated cell-culture data only; independent assay replication not identified.
- Superiority over other matrikine peptides — Not established; manufacturer in vitro fibroblast comparisons under controlled culture conditions are not substitutes for head-to-head in vivo clinical efficacy data.
Myths and misconceptions
- "Syn-Coll activates TGF-β the same way TSP-1 does" — The KVK mimicry of TSP-1's KRFK activation motif at the LAP/LSKL interface is the manufacturer's proposed mechanism, not an independently confirmed biochemical equivalence. The underlying TSP-1/TGF-β pathway is well established; whether KVK engages it in the same way remains unconfirmed outside manufacturer-controlled studies.
- "Syn-Coll produces collagen remodeling comparable to professional in-office treatments" — Topical cosmeceutical peptides produce modest, incremental changes in fibroblasts they actually reach. Treatments producing substantial collagen remodeling — fractional laser, microneedling with radiofrequency, injectable biostimulators — operate at different depth and scale. Syn-Coll does not substitute for these.
- "Higher-concentration products give proportionally better results" — Manufacturer data show roughly 12% wrinkle reduction at 2.5% versus 7% at 1%, a real but modest dose-response. The bottleneck above typical cosmetic concentrations is stratum corneum penetration and delivery to viable fibroblasts, not bulk peptide amount in the serum.
- "Because it activates a natural pathway, Syn-Coll has no safety concerns" — TGF-β is a pleiotropic cytokine with roles in tissue remodeling, fibrosis, immune modulation, and tumor microenvironment biology (Miyazono and colleagues, Frontiers of Medicine, 2018; Tzavlaki and colleagues 2020). Topical cosmeceutical exposure keeps activity localized to skin and is generally well-tolerated, but "mimics a natural pathway" does not mean the pathway has no theoretical considerations.
Safety signals
- Topical tolerability at tested concentrations (up to 2.5%): No significant irritation or adverse reactions were reported in manufacturer clinical studies; widespread cosmeceutical use without an identified safety signal in available sources.
- Contact dermatitis / hypersensitivity: Uncommon in cosmeceutical use; may relate to vehicle components (preservatives, fragrances, emulsifiers) as well as the peptide itself.
- Application to compromised skin: Available sources note increased irritation potential on broken, irritated, or actively inflamed skin; intact skin barrier is the appropriate application context.
- TGF-β pleiotropic potential: TGF-β is a pleiotropic cytokine; topical cosmeceutical exposure is localized to skin. Available sources describe application near areas of active or recent cutaneous malignancy as warranting particular caution given TGF-β's complex roles in tumor microenvironment biology.
- Injection of cosmetic preparations: Cosmetic Syn-Coll preparations are not sterile injectables and are not manufactured under injectable standards; no authorized injectable category exists; available literature notes documented infection risk from injecting cosmetic peptide preparations.
- Pregnancy and breastfeeding: No dedicated safety data identified. Available sources describe a conservative approach as appropriate given TGF-β pathway involvement in tissue remodeling.
- Long-term topical safety: Most studies run 4–12 weeks. The Cosmetic Ingredient Review (CIR) panel has assessed palmitoyl oligopeptides as safe for topical cosmetic use at typical formulation levels; long-term clinical trial data for Syn-Coll specifically have not been identified.
No controlled systemic or injectable safety data are available.
Regulatory status
- US (FDA): Cosmetic ingredient; not an approved drug. Listed under INCI as Palmitoyl Tripeptide-5; regulated under FDA cosmetic law; over-the-counter sale in finished cosmetic formulations is permitted; labels are limited to cosmetic appearance claims.
- EU: Permitted cosmetic ingredient (CosIng database).
- UK, Canada, Australia, Japan: Permitted cosmetic ingredient across these markets per available sources.
- CIR: Palmitoyl oligopeptides assessed as safe for topical cosmetic use at typical formulation levels.
- WADA: Not listed as prohibited; topical cosmetic use results in negligible systemic exposure; not characterized as a doping concern.
Mechanism
Syn-Coll (Pal-Lys-Val-Lys) is designed to mimic the TGF-β–activating function of thrombospondin-1 (TSP-1). In established extracellular matrix biology, TSP-1 activates latent TGF-β through its KRFK sequence (K412–R–F–K415 in the second type 1 repeat), which engages the LSKL motif in the latency-associated peptide (LAP) — displacing LAP from the mature TGF-β domain and enabling receptor binding (Robertson and colleagues 2016; Martinez-Hackert and colleagues 2021). Syn-Coll's Lys-Val-Lys tripeptide sequence is proposed to engage a comparable activation mechanism at the LAP interface. This specific structural and binding claim rests primarily on manufacturer-associated data; independent structural or biochemical confirmation has not been identified in available literature.
When TGF-β binds its type I/II serine-threonine kinase receptors on dermal fibroblasts, it initiates SMAD2/3-dependent transcriptional signaling, upregulating genes encoding type I collagen (COL1A1/COL1A2), type III collagen (COL3A1), fibronectin, and other extracellular matrix components (Tzavlaki and colleagues 2020). Manufacturer-associated human dermal fibroblast studies showed increased type I and III collagen mRNA and protein levels following Syn-Coll treatment, alongside downregulation of MMP-1 (interstitial collagenase) and MMP-3 (stromelysin-1). This dual mechanism — stimulating collagen neosynthesis while inhibiting enzymatic collagen degradation — is the mechanistic rationale for topical anti-wrinkle use.
The palmitoyl conjugation serves a delivery function: palmitic acid improves partition into the stratum corneum lipid bilayer relative to an unconjugated tripeptide. Even so, the fraction of applied Pal-KVK that reaches viable dermal fibroblasts in a typical cosmetic vehicle is described in available literature as small, and the delivery bottleneck — rather than peptide potency at the target cell — is identified as the primary explanation for the gap between in vitro fibroblast activity and in vivo clinical wrinkle-depth effects.
Open questions
- Independent clinical confirmation: All identified human clinical evidence is manufacturer-associated (Pentapharm/DSM). Non-industry-funded controlled human trials measuring wrinkle-depth or skin-firmness endpoints for Syn-Coll as a single ingredient are absent from available literature.
- Mechanistic confirmation of KVK–KRFK functional equivalence: The claim that Syn-Coll's KVK tripeptide functionally mimics TSP-1's KRFK activation motif at the LAP/LSKL interface has not been confirmed by independent structural, binding, or biochemical studies. This is foundational to the mechanistic rationale.
- In vivo skin penetration quantification: The fraction of applied Pal-KVK reaching viable dermal fibroblasts in commercial formulations is poorly characterized across vehicle types.
- Head-to-head comparison with other matrikine peptides: Whether Syn-Coll produces meaningfully different or superior outcomes compared with Matrixyl-family peptides or GHK-Cu has not been established by independent in vivo clinical trials.
- Long-term use data: Published studies run 4–12 weeks. Whether continuous topical use over months to years sustains benefit, attenuates, or carries any signal related to sustained localized TGF-β activation has not been studied.
Related peptides
- Matrixyl (Palmitoyl Tripeptide-1) — the other major Pentapharm palmitoyl matrikine peptide; activates collagen synthesis via a different signal (pro-collagen I C-terminal peptide mimicry) rather than TSP-1 mimicry; similar topical anti-wrinkle application.
▸full evidence table1 metrics
| metric | value | tool |
|---|---|---|
| ranking score | 0.6688986420631409 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | none_monomer |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-23 |
▸citationbibtex
@peptide{pep10770,
sequence = {KVK},
target = {cosmeceutical},
author = {peptidemodel},
year = {2026},
status = {computed}
}